Plumas Bancorp is a banks-regional business based in the US. Plumas Bancorp shares (PLBC) are listed on the NASDAQ and all prices are listed in US Dollars. Plumas Bancorp employs 158 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Experienced Investors
Our top pick for
Large Accounts
| Latest market close | $37.26 |
|---|---|
| 52-week range | $19.29 - $35.94 |
| 50-day moving average | $32.53 |
| 200-day moving average | $30.87 |
| Wall St. target price | N/A |
| PE ratio | 11.1456 |
| Dividend yield | $0.52 (1.46%) |
| Earnings per share (TTM) | $3.22 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $37.26 from 2021-10-19
| 1 week (2021-10-13) | 5.55% |
|---|---|
| 1 month (2021-09-21) | 20.50% |
| 3 months (2021-07-21) | 13.74% |
| 6 months (2021-04-21) | 31.89% |
| 1 year (2020-10-20) | 82.65% |
|---|---|
| 2 years (2019-10-18) | 72.53% |
| 3 years (2018-10-19) | 34.42% |
| 5 years (2016-10-20) | 223.58% |
Valuing Plumas Bancorp stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Plumas Bancorp's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Plumas Bancorp's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Plumas Bancorp shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $47.2 million |
|---|---|
| Operating margin TTM | 49.58% |
| Gross profit TTM | $43.7 million |
| Return on assets TTM | 1.47% |
| Return on equity TTM | 16.93% |
| Profit margin | 35.82% |
| Book value | $20.54 |
| Market capitalisation | $208.6 million |
TTM: trailing 12 months
There are currently 10,634 Plumas Bancorp shares held short by investors – that's known as Plumas Bancorp's "short interest". This figure is 28.8% down from 14,939 last month.
There are a few different ways that this level of interest in shorting Plumas Bancorp shares can be evaluated.
Plumas Bancorp's "short interest ratio" (SIR) is the quantity of Plumas Bancorp shares currently shorted divided by the average quantity of Plumas Bancorp shares traded daily (recently around 5317). Plumas Bancorp's SIR currently stands at 2. In other words for every 100,000 Plumas Bancorp shares traded daily on the market, roughly 2000 shares are currently held short.
However Plumas Bancorp's short interest can also be evaluated against the total number of Plumas Bancorp shares, or, against the total number of tradable Plumas Bancorp shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Plumas Bancorp's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Plumas Bancorp shares in existence, roughly 0 shares are currently held short) or 0.0022% of the tradable shares (for every 100,000 tradable Plumas Bancorp shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Plumas Bancorp.
Find out more about how you can short Plumas Bancorp stock.
Dividend payout ratio: 16.03% of net profits
Recently Plumas Bancorp has paid out, on average, around 16.03% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.56% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Plumas Bancorp shareholders could enjoy a 1.56% return on their shares, in the form of dividend payments. In Plumas Bancorp's case, that would currently equate to about $0.52 per share.
While Plumas Bancorp's payout ratio might seem low, this can signify that Plumas Bancorp is investing more in its future growth.
Plumas Bancorp's most recent dividend payout was on 15 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 July 2021 (the "ex-dividend date").
Plumas Bancorp's shares were split on a 3:2 basis on 18 September 2005. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Plumas Bancorp shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Plumas Bancorp shares which in turn could have impacted Plumas Bancorp's share price.
Over the last 12 months, Plumas Bancorp's shares have ranged in value from as little as $19.2877 up to $35.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Plumas Bancorp's is 0.627. This would suggest that Plumas Bancorp's shares are less volatile than average (for this exchange).
Plumas Bancorp operates as the bank holding company for the Plumas Bank that provides various banking products and services for small and middle market businesses, and individuals in Northeastern California and Northwestern Nevada. The company offers various deposit products, such as checking, interest-bearing checking, public funds and business sweep, savings, and retirement accounts, as well as time and remote deposits. Its loan portfolio comprises consumer loans, including residential equity lines of credit and automobile loans; real estate, and commercial and industrial term loans; government-guaranteed and agricultural loans; land development and construction loans; and credit lines. The company also provides cashier's check, bank-by-mail, automated teller machine (ATM), night depository, safe deposit box, direct deposit, electronic funds transfer, and other customary banking services, as well as telephone and mobile banking services, including mobile deposit and Internet banking services with bill-pay options. It operates 11 branches located in Plumas, Lassen, Placer, Nevada, Modoc, and Shasta counties, California; and 2 branches situated in Washoe and Carson City counties, Nevada, as well as 2 loan production offices located in Placer and Butte counties, California; and 1 loan production office situated in the Oregon County of Klamath. The company also operates 17 ATMs. Plumas Bancorp was founded in 1980 and is headquartered in Reno, Nevada.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.